An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Brief description of study

This study seeks to roll over subjects from ISIS 678354-CS3 (the index study; Penn IRB#850921). Patients will receive drug at the dose of 80 mg every 4 weeks (or 50 mg every-4-weeks if their dose was permanently reduced from 80 mg to 50 mg (ISIS 678354 or placebo) in the index study) during Weeks 1-153 of a 157-week Treatment Period, followed by a 13-week Post-Treatment Follow-up Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: Between 18 Years - 99 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 853109

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).